Literature DB >> 19383188

Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.

M Martins1, M Viveiros, I Couto, L Amaral.   

Abstract

Although many compounds have been described to inhibit the replication of drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, most of these studies only evaluate their in vitro activity. There is a lack of studies that show whether any of these agents can kill these organisms at the site where they normally reside post infection, namely, the macrophage of the lung parenchyma. It is the aim of this mini-review to identify agents that have been shown to enhance the killing of intracellular drug-susceptible, multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains by non-killing macrophages. Because these agents appear to promote their activity by affecting the transport of K(+) and Ca(2+) from the phagolysosome containing the bacteria, and thereby promoting its acidification and activation of hydrolases that will eventually kill the organism, the authors suggest that compounds that are known to affect the transport of K(+) and Ca(2+) should be considered for possible activity against intracellular MDR- and XDR-TB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383188

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

Review 1.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

Review 2.  Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.

Authors:  Maria Hassan Kiani; Muhammad Imran; Abida Raza; Gul Shahnaz
Journal:  Daru       Date:  2020-03-19       Impact factor: 3.117

Review 3.  Nanomedicine as an emerging approach against intracellular pathogens.

Authors:  Andrea L Armstead; Bingyun Li
Journal:  Int J Nanomedicine       Date:  2011-12-09

4.  Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.

Authors:  Diana Machado; David Pires; João Perdigão; Isabel Couto; Isabel Portugal; Marta Martins; Leonard Amaral; Elsa Anes; Miguel Viveiros
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

5.  Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them.

Authors:  Leonard Amaral; Ana Martins; Gabriella Spengler; Joseph Molnar
Journal:  Front Pharmacol       Date:  2014-01-03       Impact factor: 5.810

6.  Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient.

Authors:  Leonard Amaral; Joseph Molnar
Journal:  Pharmaceuticals (Basel)       Date:  2012-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.